サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1779899

涙嚢炎の世界市場

Dacryocystitis

出版日
ページ情報
英文 374 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
涙嚢炎の世界市場
出版日: 2025年07月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 374 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

涙嚢炎の世界市場は2030年までに5,120万米ドルに達する見込み

2024年に4,120万米ドルと推定される涙嚢炎の世界市場は、2024年から2030年にかけてCAGR 3.7%で成長し、2030年には5,120万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである外科治療は、CAGR 4.6％を記録し、分析期間終了時には2,770万米ドルに達すると予測されます。薬物治療セグメントの成長率は、分析期間中CAGR 2.6％と推定されます。

米国市場は1,120万米ドルと推定、中国はCAGR7.0％で成長予測

米国の涙嚢炎市場は2024年に1,120万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 7.0％で推移し、2030年には予測市場規模1,040万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4％と2.9％と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の涙嚢炎市場- 主要動向と市場促進要因のまとめ

涙嚢炎が眼科で注目される理由とは？

涙嚢の感染症または炎症である涙嚢炎は、膿瘍形成や視力障害などの合併症の可能性があるため、眼科で関心が高まっています。涙嚢炎は、細菌感染、外傷、涙の排出システムの障害によって引き起こされることが多く、痛みを伴う腫れ、過度の涙、膿の排出を引き起こします。涙嚢炎を治療せずに放置すると、眼窩蜂窩織炎や全身感染症に進行する可能性があり、早期の診断と治療が不可欠です。

加齢に伴う眼障害、新生児の先天性涙道閉塞症、手術後の合併症の有病率の上昇により、涙嚢炎の発生率は増加しています。さらに、コンタクトレンズ使用者やまぶたの美容整形手術を受ける人の増加により、涙道感染症のリスクが高まっています。低侵襲手術手技と抗生物質療法の進歩は、患者の転帰を改善し、効果的な治療ソリューションの需要を促進しています。

涙嚢炎治療における最新のイノベーションとは？

涙嚢炎の治療は、高度な抗生物質療法、低侵襲手術、新しいドラッグデリバリーシステムの導入により進化してきました。最も重要な進歩のひとつは、内視鏡下涙嚢形成術（DCR）です。これは、外から切開することなく、新しい涙の排出経路を作る低侵襲の手術法です。この手技は、慢性的な涙嚢炎の治療法として好まれるようになり、瘢痕形成や回復に要する時間を短縮しています。

さらに、生分解性薬剤溶出ステントを使用することで、涙道再閉塞を防ぎ、感染リスクを低減することで、術後の転帰を改善しています。ナノ粒子ベースの抗生物質点眼薬も、薬剤の浸透性を高め、抗菌活性を長持ちさせるために開発されています。ダクライオシンチグラフィや超音波検査など、AIを活用した診断ツールや画像技術は、涙嚢炎の早期発見や個別治療に役立っています。

市場動向と規制ガイドラインは涙嚢炎治療にどのような影響を与えているか？

低侵襲性眼科手術の採用が増加し、高度な抗菌療法への需要が涙嚢炎治療の展望を形成しています。開発途上地域におけるヘルスケアインフラの拡大は、眼科医療サービスへのアクセスを改善し、涙道感染症の早期診断と治療を促進しています。さらに、老年人口の増加と慢性炎症性眼疾患の有病率の増加が市場の需要を促進しています。

米国FDAや欧州医薬品庁（European Medicines Agency）などの規制機関は、眼科用医薬品の製剤や治療に使用される医療機器に厳格なガイドラインを適用しています。抗生物質の点眼薬、ステント、手術器具を開発するメーカーにとって、無菌性と生体適合性の基準を遵守することは極めて重要です。さらに、遠隔医療やデジタルヘルスプラットフォームの動向は、涙嚢炎患者の遠隔診察や処方管理を可能にしています。

涙嚢炎市場の成長の原動力は？

涙嚢炎市場の成長を牽引しているのは、眼科手術の進歩、抗生物質耐性感染症の増加、眼疾患の早期管理に対する意識の高まりです。内視鏡的DCRや非侵襲的ドラッグデリバリーシステムの採用により、合併症を最小限に抑えながら治療成績が向上しています。

最終用途の拡大も重要な要因であり、涙嚢炎治療は小児眼科、手術後の眼科医療、高齢者医療で重視されるようになっています。眼科診断におけるAIと機械学習の統合も、涙道評価の精度を高めています。さらに、患者固有の抗生物質レジメンやカスタマイズされた手術手技など、個別化された治療アプローチの開発は、涙嚢炎管理の未来を形成しています。眼科研究が進歩し続ける中、涙嚢炎市場は着実に成長し、眼感染症治療や外科治療の革新を支えていくと予想されます。

セグメント

治療タイプ（外科治療、投薬治療）、適応症（慢性涙嚢炎治療、急性涙嚢炎治療、先天性涙嚢炎治療）、販売チャネル（機関販売チャネル、小売販売チャネル）

調査対象企業の例

  • Alcon Inc.
  • Aurobindo Pharma Limited
  • Aurolab
  • Bausch Health Companies Inc.
  • Bayer AG
  • Beaver-Visitec International
  • Bess Medizintechnik GmbH
  • BVM Medical Limited
  • F. Hoffmann-La Roche Ltd（Genentech, Inc.）
  • FCI Ophthalmics（part of ZEISS Group）
  • Fruida
  • GlaxoSmithKline plc
  • Gunther Weiss Scientific Glassblowing Co., Inc.
  • Kaneka Corporation
  • Merck & Co., Inc.
  • Mylan N.V.（now part of Viatris Inc.）
  • Nosch Labs Pvt Ltd
  • Orex Pharma Pvt Ltd
  • Pfizer Inc.
  • Sinopsys Surgical

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30345

Global Dacryocystitis Market to Reach US$51.2 Million by 2030

The global market for Dacryocystitis estimated at US$41.2 Million in the year 2024, is expected to reach US$51.2 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Surgical Treatment, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$27.7 Million by the end of the analysis period. Growth in the Medication Treatment segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Million While China is Forecast to Grow at 7.0% CAGR

The Dacryocystitis market in the U.S. is estimated at US$11.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.4 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Dacryocystitis Market - Key Trends & Growth Drivers Summarized

Why Is Dacryocystitis Becoming a Growing Concern in Ophthalmology?

Dacryocystitis, an infection or inflammation of the lacrimal sac, is becoming an increasing concern in ophthalmology due to its potential complications, including abscess formation and vision impairment. The condition is often caused by bacterial infections, trauma, or obstructions in the tear drainage system, leading to painful swelling, excessive tearing, and pus discharge. If left untreated, dacryocystitis can progress to orbital cellulitis or systemic infections, making early diagnosis and treatment essential.

The rising prevalence of age-related eye disorders, congenital tear duct obstructions in newborns, and post-surgical complications has increased the incidence of dacryocystitis. Additionally, the growing number of contact lens users and individuals undergoing aesthetic eyelid surgeries has contributed to a higher risk of tear duct infections. Advancements in minimally invasive surgical techniques and antibiotic therapies are improving patient outcomes, driving demand for effective treatment solutions.

What Are the Latest Innovations in Dacryocystitis Treatment?

The treatment of dacryocystitis has evolved with the introduction of advanced antibiotic therapies, minimally invasive procedures, and novel drug delivery systems. One of the most significant advancements is endoscopic dacryocystorhinostomy (DCR), a minimally invasive surgical procedure that creates a new tear drainage pathway without external incisions. This technique has become the preferred treatment for chronic dacryocystitis, reducing scarring and recovery time.

Additionally, the use of biodegradable drug-eluting stents is improving post-surgical outcomes by preventing tear duct re-blockage and reducing infection risks. Nanoparticle-based antibiotic eye drops are also being developed to enhance drug penetration and prolong antibacterial activity. AI-driven diagnostic tools and imaging techniques, such as dacryoscintigraphy and ultrasonography, are aiding in the early detection and personalized treatment of dacryocystitis.

How Are Market Trends and Regulatory Guidelines Influencing Dacryocystitis Treatment?

The increasing adoption of minimally invasive ophthalmic surgeries and the demand for advanced antimicrobial therapies are shaping the dacryocystitis treatment landscape. The expansion of healthcare infrastructure in developing regions has improved access to eye care services, facilitating early diagnosis and treatment of tear duct infections. Additionally, the rising geriatric population and the growing prevalence of chronic inflammatory eye conditions are fueling market demand.

Regulatory agencies, such as the U.S. FDA and the European Medicines Agency, are enforcing strict guidelines on ophthalmic drug formulations and medical devices used in dacryocystitis treatment. Compliance with sterility and biocompatibility standards is crucial for manufacturers developing antibiotic eye drops, stents, and surgical instruments. Additionally, the trend toward telemedicine and digital health platforms is enabling remote consultation and prescription management for dacryocystitis patients.

What Is Driving the Growth of the Dacryocystitis Market?

The growth in the dacryocystitis market is driven by advancements in ophthalmic surgery, increasing antibiotic-resistant infections, and rising awareness of early eye disease management. The adoption of endoscopic DCR and non-invasive drug delivery systems is improving treatment outcomes while minimizing complications.

End-use expansion is another critical factor, with dacryocystitis treatment becoming a focus in pediatric ophthalmology, post-surgical eye care, and geriatric medicine. The integration of AI and machine learning in ophthalmic diagnostics is also enhancing the accuracy of tear duct assessments. Additionally, the development of personalized treatment approaches, including patient-specific antibiotic regimens and customized surgical techniques, is shaping the future of dacryocystitis management. As ophthalmic research continues to advance, the dacryocystitis market is expected to grow steadily, supporting innovations in eye infection treatment and surgical care.

SCOPE OF STUDY:

The report analyzes the Dacryocystitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Surgical Treatment, Medication Treatment); Indication (Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment, Congenital Dacryocystitis Treatment); Sales Channel (Institutional Sales Channel, Retail Sales Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Alcon Inc.
  • Aurobindo Pharma Limited
  • Aurolab
  • Bausch Health Companies Inc.
  • Bayer AG
  • Beaver-Visitec International
  • Bess Medizintechnik GmbH
  • BVM Medical Limited
  • F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • FCI Ophthalmics (part of ZEISS Group)
  • Fruida
  • GlaxoSmithKline plc
  • Gunther Weiss Scientific Glassblowing Co., Inc.
  • Kaneka Corporation
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Nosch Labs Pvt Ltd
  • Orex Pharma Pvt Ltd
  • Pfizer Inc.
  • Sinopsys Surgical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Dacryocystitis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Chronic and Acute Tear Duct Infections Elevating Diagnosis Rates
    • Growth in Elderly Population Driving Susceptibility to Lacrimal Disorders
    • Rising Adoption of Minimally Invasive Dacryocystorhinostomy (DCR) Procedures
    • Technological Advancements in Endoscopic and Laser-Assisted Surgeries
    • Use of Imaging and Diagnostic Tools Enhancing Early Detection and Classification
    • Expanding Access to Ophthalmic Care in Emerging Economies Supporting Treatment Volumes
    • Wider Use of Broad-Spectrum Antibiotics Driving First-Line Management Options
    • Increased Availability of Tear Drainage Stents and Implants Improving Recovery Outcomes
    • Integration of Dacryocystitis Screening in Routine Eye Examinations Boosting Awareness
    • Growing Training and Expertise in Oculoplastic Surgery Enhancing Surgical Success Rates
    • Emergence of Single-Use and Disposable Surgical Instruments Supporting Infection Control
    • Use of Culture-Guided Therapy in Recurrent Cases Enhancing Treatment Efficacy
    • Increased Awareness Among Primary Care Providers Promoting Referrals
    • Growth in Pediatric Cases Leading to Improved Early Intervention Techniques
    • Innovations in Topical and Injectable Therapies Driving Outpatient Treatment Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dacryocystitis Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Dacryocystitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Surgical Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chronic Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acute Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acute Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Acute Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Congenital Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Congenital Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Congenital Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Institutional Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Institutional Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Institutional Sales Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Sales Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Dacryocystitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Dacryocystitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Dacryocystitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Dacryocystitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Dacryocystitis by Treatment Type - Surgical Treatment and Medication Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Dacryocystitis by Treatment Type - Percentage Breakdown of Value Sales for Surgical Treatment and Medication Treatment for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Dacryocystitis by Indication - Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Dacryocystitis by Indication - Percentage Breakdown of Value Sales for Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment and Congenital Dacryocystitis Treatment for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Dacryocystitis by Sales Channel - Institutional Sales Channel and Retail Sales Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Dacryocystitis by Sales Channel - Percentage Breakdown of Value Sales for Institutional Sales Channel and Retail Sales Channel for the Years 2015, 2025 & 2030

IV. COMPETITION